Cargando…

Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study

Relevant resistance-associated substitutions (RASs) to elbasvir, the new HCV NS5A inhibitor, may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are few data outside clinical trials evaluating their prevalence and impact of elbasvir/grazoprevir. A multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palladino, Claudia, Sánchez-Carrillo, Marta, Mate-Cano, Irene, Vázquez-Morón, Sonia, Jimenez-Sousa, Ma Ángeles, Gutiérrez-Rivas, Mónica, Resino, Salvador, Briz, Verónica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460287/ https://www.ncbi.nlm.nih.gov/pubmed/28588311 http://dx.doi.org/10.1038/s41598-017-02968-7

Ejemplares similares

NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain
por: Jimenez-Sousa, María Ángeles, et al.
Publicado: (2016)

Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain
por: Palladino, Claudia, et al.
Publicado: (2020)

Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000–2015): A Nationwide Study
por: Alvaro-Meca, Alejandro, et al.
Publicado: (2020)

The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
por: Tsai, Tzu‐Cheng, et al.
Publicado: (2019)

Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China
por: Liu, Jinyu, et al.
Publicado: (2021)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012–2014)
por: Vázquez-Morón, Sonia, et al.
Publicado: (2019)

HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study
por: Ryan, Pablo, et al.
Publicado: (2021)

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
por: Liu, Chen-Hua, et al.
Publicado: (2020)

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
por: Lee, Youn Jae, et al.
Publicado: (2019)

Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
por: Puenpatom, Amy, et al.
Publicado: (2020)

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events
por: Kanda, Tatsuo, et al.
Publicado: (2018)

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis
por: Yao, Yinan, et al.
Publicado: (2017)

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
por: Chen, Jin, et al.
Publicado: (2020)

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
por: Zhdanov, Konstantin, et al.
Publicado: (2020)

The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir/grazoprevir regimens in the United States
por: Elbasha, E. H., et al.
Publicado: (2016)

Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
por: George, Jacob, et al.
Publicado: (2018)

Safety and efficacy of elbasvir/grazoprevir in patients infected with hepatitis C virus genotype 4 in Qassim region of Saudi Arabia
por: Murgod, Shivananda E., et al.
Publicado: (2023)

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy
por: Bertoli, Ada, et al.
Publicado: (2018)

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study
por: Jacobson, Ira M., et al.
Publicado: (2019)

Discovery and mechanistic study of a photocatalytic indoline dehydrogenation for the synthesis of elbasvir
por: Yayla, Hatice G., et al.
Publicado: (2016)

Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients
por: Aldunate, Fabián, et al.
Publicado: (2018)

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry
por: Hinrichsen, Holger, et al.
Publicado: (2020)

Comparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfected patients
por: Martínez-González, Elena, et al.
Publicado: (2020)

Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study
por: Gonzalez-Peralta, Regino P., et al.
Publicado: (2023)

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis
por: Pineda-Tenor, Daniel, et al.
Publicado: (2015)

Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”
por: Eybpoosh, Sana, et al.
Publicado: (2018)

Pneumocystis pneumonia in HIV-positive patients in Spain: epidemiology and environmental risk factors
por: Alvaro-Meca, Alejandro, et al.
Publicado: (2015)

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
por: Bell, Allison M., et al.
Publicado: (2016)

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
por: Morikawa, Kenichi, et al.
Publicado: (2018)

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients
por: Ji, Qinghua, et al.
Publicado: (2021)

Response to: Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”
por: Aldunate, Fabián, et al.
Publicado: (2019)

Parvovirus B19 Genotype Specific Amino Acid Substitution in NS1 Reduces the Protein's Cytotoxicity in Culture
por: Kivovich, Violetta, et al.
Publicado: (2010)

Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis
por: Uchida, Yoshihito, et al.
Publicado: (2018)

A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir
por: Fernandes Campos, Guilherme Rodrigues, et al.
Publicado: (2020)

Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C
por: Suraweera, Duminda, et al.
Publicado: (2016)

Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment
por: Weiss, Lina, et al.
Publicado: (2018)

Hepatic Failure Due to Cholestatic Hepatitis C in an Immunosuppressed Patient Treated With Elbasvir and Grazeprevir
por: Nassar, Amin H., et al.
Publicado: (2018)

Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
por: Ng, Xinyi, et al.
Publicado: (2018)

No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole
por: Feng, H‐P, et al.
Publicado: (2017)

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
por: Liu, Jinyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s4lbbsntp7a9io07kueu0onmr7